AbbVie strikes US$713M monoclonal antibody deal with OSE Immunotherapeutics  

AbbVie strikes US$713M monoclonal antibody deal with OSE Immunotherapeutics  

USA— AbbVie and OSE Immunotherapeutics have forged a partnership and licensing agreement for the latter’s monoclonal antibody, OSE-230, in a deal valued at up to US$713 million.  

 OSE-230 targets the G-Protein coupled receptor (GPCR) known as ChemR23. The treatment, currently in the preclinical development stage, holds promise for reducing persistent inflammation and modifying neutrophil and macrophage activity. 

 Per the terms of the collaboration agreement, AbbVie will make an upfront payment of $48 million for the therapy’s exclusive worldwide license. Moreover, OSE stands to receive tiered royalties on net sales and milestone-based payments worth up to $665 million. 

 OSE is actively collaborating with other pharmaceutical entities to establish a pipeline of several monoclonal antibody candidates. In partnership with Boehringer Ingelheim, the company is advancing two monoclonal antibodies targeting signal regulatory protein α (SIRPα): BI 765063/OSE-172 and BI 770371. 

In a Phase I trial (NCT05249426), BI 765063 is under evaluation in combination with various cancer medicines, including chemotherapy, Boehringer’s ezabenlimab, BI 836880, and Eli Lilly’s Erbitux (cetuximab).  

An international Phase I dose escalation and expansion trial (NCT05327946) is enrolling patients with solid tumors to assess BI 770371 both as a monotherapy and in conjunction with a PD1 inhibitor, BI 754091. 

 In collaboration with Veloxis Pharmaceuticals of Denmark, OSE is also progressing with FR104/VEL-101, an anti-CD28 selective monoclonal antibody.  

This medication, under Phase II trials for the subcutaneous treatment, is being studied as a potential treatment to help kidney transplant recipients avoid organ rejection.  

The FDA granted the treatment a fast-track designation in February 2022 for the prevention of transplant rejection. 

 Meanwhile, AbbVie has recently expanded its portfolio in antibody treatments, teaming up with BigHat Biosciences in December 2023 to discover and develop antibody treatments for neurological and oncological diseases. 

In a broader move, AbbVie announced in November 2023 its plans to acquire ImmunoGen for $10.1 billion. A central aspect of the deal was the antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx).  

The US Food and Drug Administration accorded priority evaluation to the therapy, with a Prescription Drug User Fee Act (PDUFA) action date set for April 5, 2024. 

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.

Leave a reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.